ICON Public (NASDAQ:ICLR) Releases FY 2024 Earnings Guidance

ICON Public (NASDAQ:ICLR) issued an update on its FY 2024 earnings guidance on Saturday morning. The company provided earnings per share (EPS) guidance of 15.000-15.200 for the period, compared to the consensus estimate of 15.060. The company issued revenue guidance of $8.5 billion-$8.6 billion, compared to the consensus revenue estimate of $8.6 billion.

ICON Public Stock Performance

Shares of NASDAQ ICLR traded up $10.36 during midday trading on Friday, reaching $323.46. 908,602 shares of the company were exchanged, compared to its average volume of 788,375. The company has a current ratio of 1.31, a quick ratio of 1.21 and a debt-to-equity ratio of 0.36. ICON Public has a 1 year low of $221.20 and a 1 year high of $347.72. The stock has a fifty day simple moving average of $322.17 and a 200 day simple moving average of $308.87. The stock has a market cap of $26.69 billion, a P/E ratio of 39.35, a PEG ratio of 1.40 and a beta of 1.23.

ICON Public (NASDAQ:ICLR) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.68 by $0.07. The firm had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.14 billion. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The business’s revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the company posted $2.96 earnings per share. On average, research analysts forecast that ICON Public will post 14.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ICLR. Evercore ISI reduced their price objective on shares of ICON Public from $350.00 to $330.00 and set an outperform rating for the company in a research report on Friday, April 26th. Mizuho reiterated a buy rating and set a $346.00 price target on shares of ICON Public in a research report on Thursday, April 4th. The Goldman Sachs Group started coverage on shares of ICON Public in a research report on Thursday, June 6th. They set a buy rating and a $370.00 price target for the company. Truist Financial lifted their price target on shares of ICON Public from $367.00 to $383.00 and gave the company a buy rating in a research report on Friday. Finally, Barclays reduced their price target on shares of ICON Public from $355.00 to $350.00 and set an overweight rating for the company in a research report on Friday. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus price target of $352.56.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.